Except for one patient (case 16) who developed a MDS-AML with biallelic mutations of the CEBPA gene, all patients were heavily pretreated, two with conventional chemotherapy for two (case 27) and one (case 10) prior relapse, and three (cases 9, 10, and 13) were retreated with “MEMMAT-like” therapy for consecutive relapses. This evidence concerns the gene CEBPA and myelodysplastic syndrome.